Cargando…

Evaluation of reporting quality of randomized controlled trials in patients with COVID-19 using the CONSORT statement

OBJECTIVE: To evaluate the reporting quality of randomized controlled trials (RCTs) regarding patients with COVID-19 and analyse the influence factors. METHODS: PubMed, Embase, Web of Science and the Cochrane Library databases were searched to collect RCTs regarding patients with COVID-19. The retri...

Descripción completa

Detalles Bibliográficos
Autores principales: Yin, Yuhuan, Shi, Fugui, Zhang, Yiyin, Zhang, Xiaoli, Ye, Jianying, Zhang, Juxia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8460279/
https://www.ncbi.nlm.nih.gov/pubmed/34555033
http://dx.doi.org/10.1371/journal.pone.0257093
_version_ 1784571712867663872
author Yin, Yuhuan
Shi, Fugui
Zhang, Yiyin
Zhang, Xiaoli
Ye, Jianying
Zhang, Juxia
author_facet Yin, Yuhuan
Shi, Fugui
Zhang, Yiyin
Zhang, Xiaoli
Ye, Jianying
Zhang, Juxia
author_sort Yin, Yuhuan
collection PubMed
description OBJECTIVE: To evaluate the reporting quality of randomized controlled trials (RCTs) regarding patients with COVID-19 and analyse the influence factors. METHODS: PubMed, Embase, Web of Science and the Cochrane Library databases were searched to collect RCTs regarding patients with COVID-19. The retrieval time was from the inception to December 1, 2020. The CONSORT 2010 statement was used to evaluate the overall reporting quality of these RCTs. RESULTS: 53 RCTs were included. The study showed that the average reporting rate for 37 items in CONSORT checklist was 53.85% with mean overall adherence score of 13.02±3.546 (ranged: 7 to 22). The multivariate linear regression analysis showed the overall adherence score to the CONSORT guideline was associated with journal impact factor (P = 0.006), and endorsement of CONSORT statement (P = 0.014). CONCLUSION: Although many RCTs of COVID-19 have been published in different journals, the overall reporting quality of these articles was suboptimal, it can not provide valid evidence for clinical decision-making and systematic reviews. Therefore, more journals should endorse the CONSORT statement, authors should strictly follow the relevant provisions of the CONSORT guideline when reporting articles. Future RCTs should particularly focus on improvement of detailed reporting in allocation concealment, blinding and estimation of sample size.
format Online
Article
Text
id pubmed-8460279
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-84602792021-09-24 Evaluation of reporting quality of randomized controlled trials in patients with COVID-19 using the CONSORT statement Yin, Yuhuan Shi, Fugui Zhang, Yiyin Zhang, Xiaoli Ye, Jianying Zhang, Juxia PLoS One Research Article OBJECTIVE: To evaluate the reporting quality of randomized controlled trials (RCTs) regarding patients with COVID-19 and analyse the influence factors. METHODS: PubMed, Embase, Web of Science and the Cochrane Library databases were searched to collect RCTs regarding patients with COVID-19. The retrieval time was from the inception to December 1, 2020. The CONSORT 2010 statement was used to evaluate the overall reporting quality of these RCTs. RESULTS: 53 RCTs were included. The study showed that the average reporting rate for 37 items in CONSORT checklist was 53.85% with mean overall adherence score of 13.02±3.546 (ranged: 7 to 22). The multivariate linear regression analysis showed the overall adherence score to the CONSORT guideline was associated with journal impact factor (P = 0.006), and endorsement of CONSORT statement (P = 0.014). CONCLUSION: Although many RCTs of COVID-19 have been published in different journals, the overall reporting quality of these articles was suboptimal, it can not provide valid evidence for clinical decision-making and systematic reviews. Therefore, more journals should endorse the CONSORT statement, authors should strictly follow the relevant provisions of the CONSORT guideline when reporting articles. Future RCTs should particularly focus on improvement of detailed reporting in allocation concealment, blinding and estimation of sample size. Public Library of Science 2021-09-23 /pmc/articles/PMC8460279/ /pubmed/34555033 http://dx.doi.org/10.1371/journal.pone.0257093 Text en © 2021 Yin et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Yin, Yuhuan
Shi, Fugui
Zhang, Yiyin
Zhang, Xiaoli
Ye, Jianying
Zhang, Juxia
Evaluation of reporting quality of randomized controlled trials in patients with COVID-19 using the CONSORT statement
title Evaluation of reporting quality of randomized controlled trials in patients with COVID-19 using the CONSORT statement
title_full Evaluation of reporting quality of randomized controlled trials in patients with COVID-19 using the CONSORT statement
title_fullStr Evaluation of reporting quality of randomized controlled trials in patients with COVID-19 using the CONSORT statement
title_full_unstemmed Evaluation of reporting quality of randomized controlled trials in patients with COVID-19 using the CONSORT statement
title_short Evaluation of reporting quality of randomized controlled trials in patients with COVID-19 using the CONSORT statement
title_sort evaluation of reporting quality of randomized controlled trials in patients with covid-19 using the consort statement
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8460279/
https://www.ncbi.nlm.nih.gov/pubmed/34555033
http://dx.doi.org/10.1371/journal.pone.0257093
work_keys_str_mv AT yinyuhuan evaluationofreportingqualityofrandomizedcontrolledtrialsinpatientswithcovid19usingtheconsortstatement
AT shifugui evaluationofreportingqualityofrandomizedcontrolledtrialsinpatientswithcovid19usingtheconsortstatement
AT zhangyiyin evaluationofreportingqualityofrandomizedcontrolledtrialsinpatientswithcovid19usingtheconsortstatement
AT zhangxiaoli evaluationofreportingqualityofrandomizedcontrolledtrialsinpatientswithcovid19usingtheconsortstatement
AT yejianying evaluationofreportingqualityofrandomizedcontrolledtrialsinpatientswithcovid19usingtheconsortstatement
AT zhangjuxia evaluationofreportingqualityofrandomizedcontrolledtrialsinpatientswithcovid19usingtheconsortstatement